Collegium Pharmaceutical, Inc. COLL 深 滬
已收盤 11-06 16:00:00 美东时间
24.21
-0.950
-3.78%
華盛通- 最 高24.80
- 今 開24.06
- 成交量 77.56万股
- 最 低 23.71
- 昨 收 25.16
- 總市值 7.50亿
- 52周最高 50.7866
- 市盈率 靜 13.95
- 換手率 2.50%
- 52周最低 21.43
- 委 比 -65.03%
- 總股本 3099.92万
- 歷史最高 50.7866
- 量 比 0.99
- 振 幅 4.33%
- 歷史最低 7.37
- 每 手 1
- 風險率 8.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 可口可乐、麦当劳、3M等获多家大行看好；机构上调高通目标价至165美元
今日重点评级关注：Citizens：维持Precigen"跑赢大市"评级，目标价从11美元升至12美元；Leerink Partners：维持Arcus Biosciences"跑赢大市"评级，目标价从46美元升至49美元
11-06 16:15
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $44
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $46 to $44.
11-06 01:29
Collegium Pharmaceutical Affirms FY2026 Sales Guidance of $825.000M-$855.000M vs $835.780M Est
Collegium Pharmaceutical (NASDAQ:COLL) affirms FY2026 sales outlook from $825.000 million-$855.000 million to $825.000 million-$855.000 million vs $835.780 million estimate.
11-05 20:33
Collegium Pharmaceutical Q3 Adj. EPS $1.96 Beats $1.86 Estimate, Sales $216.339M Miss $217.276M Estimate
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.96 per share which beat the analyst consensus estimate of $1.86 by 5.38 percent. This is a 12.89 percent decrease over earnings of $2.25 per share from the same period last year. The company reported quarterly sales of $216.339...
11-05 20:32
Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript
Collegium Pharmaceutical (NASDAQ:COLL) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full ear...
10-05 18:29
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50
Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $50.
09-23 18:59
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45
Leerink Partners analyst Daniel Clark initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $45.
09-09 23:16
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give...
09-03 18:09
